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ARTICLE OPEN
Chronic obstructive pulmonary disease hospital admissions
and drugs—unexpected positive associations: a retrospective
general practice cohort study
Timothy H Harries1, Paul T Seed1, Simon Jones2, Peter Schoﬁeld1 and Patrick White1
BACKGROUND: Increased prescribing of inhaled long-acting anti-muscarinic (LAMA) and combined inhaled long-acting β2-agonist
and corticosteroid (LABA+ICS) drugs for the treatment of chronic obstructive pulmonary disease (COPD) has led to hopes of
reduced hospital admissions from this disease.
AIMS: To investigate the impact of rising primary care prescribing of LAMA and LABA+ICS drugs on COPD admissions.
METHODS: This retrospective cohort study of general practice COPD admission and prescribing data between 2007 and 2010
comprised a representative group of 806 English general practices (population 5,264,506). Outcome measures were practice rates
of COPD patient admissions and prescription costs of LAMA and LABA+ICS. General practice characteristics were based on the UK
quality and outcomes framework.
RESULTS: Rates of COPD admissions remained stable from 2001 to 2010. Practice-prescribing volumes of LAMA per practice patient
and LABA+ICS per practice patient increased by 61 and 26%, respectively, between 2007 and 2010. Correlation between costs of
LAMA and those of LABA+ICS increased year on year, and was the highest in 2010 (Pearson’s r= 0.68; 95% conﬁdence interval (CI),
0.64–0.72). Practice COPD admission rates were positively predicted by practice-prescribing volumes of LAMA (2010: B= 1.23, 95%
CI, 0.61–1.85) and of LABA+ICS (2010: B= 0.32, 95% CI, 0.12–0.52) when controlling for practice list size, COPD prevalence and
deprivation.
CONCLUSION: The increase in the prescribing of LAMA and LABA+ICS inhalers was not associated with the predicted fall in hospital
admission rates for COPD patients. The positive correlation between high practice COPD prescribing and high practice COPD
admissions was not explained.
npj Primary Care Respiratory Medicine (2014) 24, Article number: 14006; doi:10.1038/npjpcrm.2014.6; published online 20 May 2014
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a leading cause
of death and of emergency hospital admissions worldwide.1,2
The efﬁcacy of COPD drugs in reducing exacerbations and
hospital admissions and improving the quality of life has been
reported in clinical trials.3–6 The success of the three main classes
of COPD drugs—the inhaled long-acting muscarinic antagonist
(LAMA) bronchodilator tiotropium, inhaled long-acting β2-agonists
(LABAs), and combined LABA and inhaled corticosteroid
(LABA+ICS) inhalers—has transformed the perception of the drug
treatment of the disease.
Drug treatment of COPD is a major cost to the UK National
Health Service (NHS). The LABA+ICS combination inhaler of
salmeterol–ﬂuticasone was the single most costly drug product
prescribed by general practitioners in England in 2011.7 Between
January 2007 and January 2011 in England the annual spending
on LAMAs increased from £78 million to £130 million, an increase
of 65%, and that on LABA+ICS increased from £385 million to £498
million, an increase of 29% (Appendix), at a time when spending
on LABAs fell by 25%.
Monotherapy with LAMA or LABA improves respiratory
symptoms and quality of life and leads to fewer COPD
exacerbations.8 Treatment with LABA+ICS (ICS monotherapy is
contraindicated in COPD) reduces the rate of moderate/severe
COPD exacerbations and reduces exacerbation-related admissions
when compared with placebo.4 When compared with LABA, LABA
+ICS signiﬁcantly reduces exacerbations with no difference in
admissions.9
Despite the beneﬁts of LAMA in reducing the frequency of
COPD exacerbations, its effect on exacerbation-related admissions
is less clear.10 When compared with placebo, the LAMA tiotropium
reduces the proportion of patients with one or more exacerba-
tions requiring hospitalisation.11,12 Subgroup analysis by severity
of the UPLIFT trial found this difference to be not signiﬁcant in
patients with severe/very severe COPD, those most likely to be
admitted with exacerbations.12
Few studies have examined the translation of these ﬁndings
into everyday clinical settings. A meta-analysis of LAMA trials and
a retrospective analysis of COPD prescribing suggested that the
effectiveness of LAMA in reducing COPD admissions in routine
practice was at best limited and in other circumstances may have
been associated with increased risk.10,13 Furthermore, a cost-utility
analysis concluded that LAMA had an unfavourable cost-
effectiveness ratio.14
In the NHS, the majority of prescribing of LAMA and LABA+ICS is
undertaken by general practitioners in the community.15 It was
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hoped that these drugs would reduce the risk of admission from
COPD and consequently reduce the healthcare-related costs of
the disease.16,17
The aim of this study was to determine whether the increasing
rates of use of LAMA and LABA+ICS in the NHS were reﬂected in a
reduction in the rate of admissions for COPD and whether general
practices with higher rates of prescribing of these drugs had fewer
COPD admissions compared with low-prescribing practices. LABAs
were excluded from the analysis because their prescription
declined throughout the study.
MATERIALS AND METHODS
Study design
We conducted a retrospective cohort study of general practice COPD
admissions and inhaler use in the English NHS using data from two
independent sources: the NHS Information Centre and the NHS Business
Services Authority (NHSBSA). Unit of analysis was NHS general practice.
Participating practices
At the time of this study, general practices in England were grouped in
Primary Care Trusts (PCTs), managerial groupings comprising around
50–60 practices.18 Selection of study practices was limited by constraints
imposed by the NHSBSA, which provided prescription-dispensing data in
response to requests made under the Freedom of Information Act 2000.19
To obtain a representative sample of practices with respect to COPD
prevalence, we stratiﬁed each PCT in England by mean COPD prevalence in
patients aged ⩾ 45 years within their respective practices and by
deprivation using the mean Index of Multiple Deprivation (IMD) score.20
IMD is a multidimensional score based on decennial national census data
and annual local authority population data reﬂecting deprivation speciﬁc
to a geographical area based on the practice address. We made a random
selection of 50 PCTs representing the distribution of characteristics by
which all PCTs were stratiﬁed. From this selection the NHSBSA made a
pragmatic selection of 15 PCTs based on the availability of dispensing data.
These were data on prescriptions dispensed for which community
pharmacists were reimbursed by the NHS.
Practice characteristics
We obtained characteristics of selected practices from the NHS Information
Centre Quality and Outcomes Framework (QOF) database for the years
2006–2010 (Appendix). QOF is the basis of a ﬁnancial incentive system
that was applied to general practices in the form of clinical and
administrative performance points.18 QOF data, to which there is open
access, included practice list size, prevalence of diagnosed COPD, IMD
scores and overall and COPD treatment-related QOF points awarded.
These demographic and performance characteristics were collected to
adjust for their effect in the analysis of the relationship between COPD
prescribing and admissions.
Inclusion criteria
Practices were included if complete data had been obtained on
prescriptions for inhaled remedies dispensed by pharmacists for at least
3 of the 4 years from 2007 to 2010 and complete COPD admission data for
at least 8 of the 10 years from 2001 to 2010. At no point were more than 23
practices (2.9%) missing from the data analysis. No allowance was made in
the analysis for missing data.
Admissions data
We obtained anonymised patient-level data on COPD patient admissions
from the NHS Information Centre Hospital Episodes Statistics database
(Appendix). A primary diagnosis ﬁeld captured all patient admissions in
England from 2001 to 2010 with a primary diagnosis of COPD (ICD-10
codes J40-J44) for patients within practices in the selected PCTs. We
undertook analysis by patient admitted per year rather than by each
admission per year to avoid the potential distortion that would be
associated with multiple admissions of the same patient.
Prescribing data
We sought prescribing data from the NHSBSA for all practices within the 15
PCTs. Data were obtainable from 2007 to 2010 and not available prior to
2007. We based our assessment on prescription costs as these were the
best estimate of the volume of prescriptions dispensed. Costs of drugs
were stable and uniform within the NHS and more accurately reﬂected the
volume of drug dispensed than the item issued, which did not include the
volume or amount of drug. We chose not to use Speciﬁc Therapeutic
group Age-sex weightings Related Prescribing Units as our unit of
prescribing as prescribing for COPD is predominantly in patients over
45 years of age. Instead, we controlled for list size, COPD prevalence and
practice deprivation in the analysis.
Total costs of NHS prescriptions dispensed presented as Net Ingredient
Cost were calculated by the NHSBSA for each practice. Net Ingredient
Cost was the cost to the NHS of each LAMA and of each LABA+ICS
drug dispensed by pharmacists from prescriptions from the study
practices (Appendix). Costs and dates of dispensing of each item were
aggregated by general practice and by PCT. Aggregated prescribing
data could only be obtained from the NHSBSA through freedom of
information enquiries. Access to data was restricted. Size limits were
imposed on each enquiry, necessitating our making 10 separate requests
to the NHSBSA between January 2011 and August 2012. Data on most
small practices were withheld by the NHSBSA to prevent the identiﬁcation
of individual prescribers, an action that would contravene the Data
Protection Act.21 The data we obtained were made available online on the
NHSBSA website (Appendix). Prescribing data obtained were independent
of underlying disease and may have represented use among asthmatic as
well as COPD patients.
Statistical methods
We based prescribing analysis on the annual prescription (dispensing)
costs of LAMA and LABA+ICS per registered practice patient (2007–2010).
Figure 1. Identiﬁcation of practices for inclusion in the study.
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We based hospital admission analysis on the annual rate of patients
admitted with a COPD exacerbation (2001–2010) per 10,000 registered
practice patients.
We sought correlations between general practices’ prescription costs per
practice patient for LAMA and their prescription costs per practice patient
for LABA+ICS from 2007 to 2010. To correct for possible spurious
correlation, we calculated the coefﬁcients of the logged costs of LAMA
and of LABA+ICS, controlling for the log of practice list size.22,23
We used multiple linear regression to examine the relationship in each
year between the prescription costs of each drug per practice patient and
the rate of COPD patients admitted per 10,000 practice patients. We
controlled for the prevalence of diagnosed COPD, IMD score and the
practice performance indicators obtained from QOF. We expressed both
predictors and outcomes as rates per practice patient, and included a
correction using the inverse of the list size (1/list size) according to the
method of Kronmal to correct for possible spurious correlation.23
As conﬁrmatory analysis we ﬁtted a multiple linear regression model,
correcting for practice list size and COPD prevalence, according to the
formula:
log (COPD patient admitted) = log (LAMA cost) + log (LABA + ICS cost)
+ log (practice list size) + log (IMD score) + log (total QOF score) + log
(COPD QOF score) + log (COPD registered patients).
We used the statistical package SPSS version 20 for data analysis. Ethical
approval was not required for this study as data were at practice level.
RESULTS
Participants
We included data from 806 practices (population 5,264,506)
(Figure 1). We excluded 215 practices because of insufﬁcient data.
Study practices differed from national practices in their greater
deprivation and prevalence of diagnosed COPD, but were no
different in practice size or drug costs (Table 1).
QOF data were available for 162 of the 215 excluded practices.
These were signiﬁcantly smaller (list size mean difference 3,599;
95% conﬁdence interval (CI), 2,991.7–4,206.2), included more
single-handed practices (58.1 vs. 8.7%) (difference 49.4%, 95% CI,
41.4–57.4) and were more deprived (IMD score mean difference
7.0; 95% CI, 4.0–10.1) than the study practices.
Prevalence of diagnosed COPD in study practices increased by
0.13% (95% CI, 0.11–0.16) from 1.79 to 1.92% from 2007 to 2010
(Figure 2). Figure 2 includes reference to the predicted national
prevalence of COPD (2.58%) in 2010.24 Prevalence of diagnosed
asthma in study practices increased by 0.21% (95% CI, 0.17–0.26)
from 5.93 to 6.14% over this period.
Prescribing data
The annual prescribing cost per practice patient (all patients) of
LAMA increased by 61% from a mean of £1.81 in 2007 to £2.90 in
2010 (mean difference £1.09, 95% CI, 1.03–1.16). LABA+ICS cost
increased by 26% from a mean of £7.87 in 2007 to £9.89 in 2010
(mean difference £2.02, 95% CI, 1.89–2.15; Figure 3). The median
(interquartile range) cost per practice patient in the same period
increased from £1.59 (1.01–2.37) to £2.66 (1.82–3.69) for LAMA and
from £7.44 (5.35–10.11) to £9.79 (7.10–12.34) for LABA+ICS.
Admissions data
The annual rate of COPD patients admitted per 10,000 practice
patients increased from a mean (s.d.) of 15.7 (10.2) in 2001 to 18.3
(10.2) in 2010 (mean difference 2.6 patients per 10,000 practice
patients, 95% CI, 1.8–3.3). The median (interquartile range) of
COPD patients admitted per 10,000 practice patients varied
between a minimum of 13.7 (8.6–20.4) in 2001 and a maximum of
16.1 (9.9–23.5) in 2003 with an annual average median
(interquartile range) of 15.5 (10.0–22.4) over 10 years.
To demonstrate the difference between COPD patients admitted
and COPD admissions, means of both, including CIs, from 2001 to
2010 are shown in Figure 4. Reference to the year of publication
(February 2003) of the ﬁrst study on the efﬁcacy of the combination
of salmeterol–ﬂuticasone in improving exacerbations in COPD is
included.3 This date was close to that of the introduction of
tiotropium in the United Kingdom (September 2002).
Prescribing correlations
The correlations between the prescribing costs of LAMA per
practice patient and those of LABA+ICS per practice patient are
Table 1. Study practices (806) compared with all other practices in
England (7,439): characteristics drawn from QOF data set 2010
Practice
characteristic
Mean (s.d.) Difference between
means (± 95% CI)
Practice list size
Study 6,517 (3,780) −166 (−133.1 to 444.7)
England 6,683 (4,228)
Males (%)
Study 50.7 (2.6) 0.4 (0.2–0.6)
England 50.3 (2.9)
Patients aged 45+ (%)
Study 39.3 (9.5) − 1.2 (−2.0 to -0.6)
England 40.5 (10.1)
Patients aged 45–64 (%)
Study 24.5 (4.9) − 0.6 (−1.0 to -0.3)
England 25.1 (4.9)
Patients aged 65–74 (%)
Study 7.8 (2.6) − 0.3 (−0.5 to − 0.1)
England 8.1 (3.0)
Patients aged 75+ (%)
Study 7.0 (2.7) − 0.3 (−0.5 to−0.1)
England 7.3 (3.8)
Deprivation score
Study 33.8 (17.6) 8.0 (6.6–9.2)
England 25.8 (17.2)
PCT cost of LABA+ICS/patient (£)
Study 9.60 (2.00) 0.57 (−0.77 to 1.90)
England 9.03 (2.54)
PCT cost of LAMA/patient (£)
Study 2.64 (0.67) 0.26 (−0.19 to 0.71)
England 2.38 (0.85)
Diagnosed COPD prevalence (%)
Study 1.93 (0.88) 0.26 (0.19–0.32)
England 1.67 (0.97)
QOF points/available
Study 0.948 (0.04) 0.001 (−0.005 to 0.003)
England 0.947 (0.05)
COPD points/available
Study 0.981 (0.06) 0.008 (0.003–0.012)
England 0.973 (0.10)
Smoking points/available
Study 0.994 (0.04) 0.002 (−0.0036 to 0.0004)
England 0.992 (0.03)
Abbreviations: CI, conﬁdence interval; COPD, chronic obstructive pulmon-
ary disease; LABA+ICS, combined inhaled long-acting β2-agonist and
corticosteroid; LAMA, long-acting anti-muscarinic; PCT, Primary Care Trust;
QOF, Quality and Outcomes Framework.
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shown in Table 2. To test for spurious correlation, partial
correlations of the log of the cost of LAMA and log of the cost
of LABA+ICS, controlling for the log of practice list size, are
included.
Regression and sensitivity analyses
Estimates for the association between prescribing costs and COPD
patient admission rates (2007–2010) are shown in Table 3. Results
were adjusted for COPD prevalence, IMD score, QOF points (total
and COPD speciﬁc) and inverse of practice size (1/practice size),
which were signiﬁcantly associated with COPD admissions in
univariate analysis.
Numbers in the table can be interpreted as additional
admissions/10,000 patients/£ spent on the drug per practice
patient.
Conﬁrmatory analysis to exclude spurious correlation was
carried out using a log transformation model of prescribing to
predict the log (base 10) of the hospital admission rate (Table 4).
A signiﬁcant increase in admissions was observed with greater
prescribing of LAMA between 2008 and 2010 and with greater
prescribing of LABA+ICS in 2007 and 2009.
DISCUSSION
Main ﬁndings
Practices that were high prescribers of LAMA and LABA+ICS drugs
had higher rates of COPD admission compared with low-
prescribing practices. This relationship was observed during a
time of signiﬁcant increase in national prescribing of both drug
classes and unchanging rates of COPD admissions. Practice rates
of prescribing of LAMA and LABA+ICS were strongly correlated.
There was no evidence of reciprocal prescribing between these
two groups of drugs whose effects on COPD in clinical trials were
similar.25 There was considerable variation in prescribing across
practices. The rates of prescribing of LAMA and LABA+ICS in those
practices within the lowest quartile were respectively less than
half and almost half of those practices within the highest quartile.
The small changes in the diagnosed prevalence of COPD and
asthma were unlikely to be responsible for the increased
prescribing of these drugs. There was no evidence of a change
in true prevalence of COPD and hence it is probable that the small
increase in diagnosed prevalence of COPD resulted from
improved recognition of the disease or changes in clinical
recording practice.
Strengths and limitations of this study
The pattern of increasing inhaled medication prescription volume
and unchanging rate of COPD patient admissions and the
consistency of the relationship between practice-level prescribing
and COPD admissions throughout the study were striking.
Prescribing data were based on NHS prescriptions dispensed, a
better reﬂection of the true impact of the drugs compared with
prescribers’ records, which would reﬂect prescriber intentions
rather than patient use. Study practices did not differ from the
practices in England other than their being situated in more
deprived areas, the most likely explanation for their high COPD
prevalence. The increase in the prescribing of COPD drugs in study
practices from 2007 to 2010 matched that in England. It is likely
that the study ﬁndings reﬂected the pattern of care in England.
Concerns regarding the accuracy of routinely collected data
sources, including Hospital Episodes Statistics admissions data,
have been ameliorated by improvements in quality over recent
Diagnosed COPD (study practices)
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Figure 2. Prevalence (% ± 95% conﬁdence interval) of diagnosed
chronic obstructive pulmonary disease (COPD) in study practices
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Figure 3. Annual rates (mean ± 95% conﬁdence interval) of LAMA
and LABA+ICS prescribing costs per practice patient (all patients).
Costs expressed based on all patients on the practice list to
standardise prescribing rates. The unit cost to the NHS of LAMA fell
by 7.3% and the unit cost to the NHS of LABA+ICS fell by up to 4.5%
between 2007 and 2010 (BNF.org). LAMA, long-acting anti-muscari-
nic; LABA+ICS, combined inhaled long-acting β2-agonist and
corticosteroid; NHS, National Health Service.
Table 2. Correlation between rates of practice prescribing cost per
practice patient of LAMA and LABA+ICS (with partial correlation of log
of the cost of LAMA and the log of the cost of LABA+ICS when
controlling for the log of the practice list size)
Rate LAMA versus Log LAMA cost versus
Year Rate LABA+ICS Log LABA+ICS cost
R1 (±95% CI) R2 (±95% CI)
2007 (n= 798) 0.52 (0.47–0.57) 0.56 (0.52–0.61)
2008 (n= 801) 0.60 (0.55–0.64) 0.63 (0.59–0.67)
2009 (n= 804) 0.63 (0.59–0.67) 0.67 (0.63–0.71)
2010 (n= 796) 0.68 (0.64– 0.72) 0.73 (0.69–0.76)
R1 is Pearson’s correlation (unadjusted for practice list size). R2 is Partial
correlation (adjusted for log practice list size). n is number of practices.
Abbreviations: CI, conﬁdence interval; LABA+ICS, combined inhaled long-
acting β2-agonist and corticosteroid; LAMA, long-acting anti-muscarinic.
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years.26 The relative stability of annual admission rates in our data
and the consistency of the relationship between admissions and
prescribing gave cause for conﬁdence.
Analysing data at a practice level rather than at patient level has
the disadvantage in a study with an ecological element such as
this of missing possible explanatory variables that are exclusive to
individual patients. Disease severity is an important example.
Another possible confounder is the actual level of use of
medication by individuals. The advantage of being able to analyse
a large cohort of practices as we have done here is that the large
number of COPD admissions observed has given us the power to
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Figure 4. Annual rates (mean ± 95% conﬁdence interval) of chronic obstructive pulmonary disease (COPD) patients admitted and of all COPD
admissions per 10,000 practice patients.
Table 3. Association of practice rates of prescribing of LAMA and LABA+ICS with practice rates of patients admitted for COPD
Associations with COPD patients admitted/10,000 patients
on the list (multiple linear regression)
Predictor variable 2007 (n=787) 2008 (n= 790) 2009 (n=797) 2010 (n= 783)
LAMA cost/practice patient, β-statistic (±95% CI) 0.37 (−0.22 to 0.97) 1.24 (0.58–1.91) 1.12 (0.55–1.70) 1.23 (0.61–1.85)
LABA+ICS cost/practice patient, β-statistic (±95% CI) 0.39 (0.22–0.56) 0.28 (0.08–0.48) 0.23 (0.05–0.41) 0.32 (0.12–0.52)
Adjusted for COPD prevalence, local deprivation (Index of Multiple Deprivation score), clinical and administrative performance (Quality and Outcomes
Framework points), and inverse of list size (1/practice size).
Abbreviations: CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; LABA+ICS, combined inhaled long-acting β2-agonist and
corticosteroid; LAMA, long-acting anti-muscarinic.
Table 4. Association between prescribing costs and COPD patient admission rates (2007–2010) using a log-transformation model to predict the log
(base 10) of the hospital admission rate
Regression outcome 2007–2010 (±95% CI)
Predictor variable 2007 2008 2009 2010
Log10 LAMA cost, β-statistic (±95% CI) 0.02 (−0.05 to 0.09) 0.22 (0.13–0.30) 0.19 (0.10–0.28) 0.29 (0.19–0.40)
Log10 LABA+ICS cost, β-statistic (±95% CI) 0.20 (0.13–0.28) 0.07 (−0.03 to 0.16) 0.11 (0.01–0.21) 0.10 (−0.01 to 0.22)
Dependent variable: Log10 COPD patients admitted.
Abbreviations: CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; LABA+ICS, combined inhaled long-acting β2-agonist and
corticosteroid; LAMA, long-acting anti-muscarinic.
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which would be impossible at individual practice level. As
admissions occur mainly among the most severely affected COPD
patients it may be surmised that the patients admitted were
predominantly those with severe disease.4,27 We cannot assume
that it was for these patients that LAMA and LABA+ICS were
prescribed. However, the positive association between prescribing
and admissions was strong throughout the study when control-
ling for prevalence, deprivation, prescribing of the other drug type
and practice performance data. It would seem perverse to suggest
that the signiﬁcant increase in prescribing took place only in those
patients who were not at risk of admission.
The association between high practice rates of prescribing of
LAMA and LABA+ICS and high practice rates of COPD admission
may be explained by larger numbers of severely affected COPD
patients being found in high prescribing practices. If this was the
case it would suggest that the drugs were ineffective at reducing
admissions, as rates of COPD admission have not fallen following
the introduction and progressive increase in rates of prescribing of
these drugs. An increased rate of prescription of LABA+ICS to
patients with asthma may have contributed to the increasing rate
of prescribing of these drugs within the practices.
Interpretation of ﬁndings in relation to previously published work
The reduction in the frequency of COPD exacerbations seen in
clinical trials of LAMA and LABA+ICS has raised the hope that
prescribing of these drugs in patients with severe and very severe
COPD would reduce COPD admissions, leading to substantial cost
savings.4,28,29 The lack of evidence for their effect in reducing
COPD admissions resonates with concerns of Suissa30 about
underestimates of the number needed to treat in clinical trials of
LABA+ICS, which assessed outcome in terms of frequency of acute
exacerbations of COPD assessed.
The positive association between prescribing costs and admis-
sions is unlikely to represent a causal relationship as there is no
evidence from clinical trials of such adverse effects. A second
possible explanation might be that patients started using these
drugs at the time of admission, leading to a cumulative effect of
admission-associated prescribing. This does not account for the
fact that the rise in drug prescribing far exceeded the small
change in the rate of COPD admissions. We consider it more
plausible that the association we have observed described the
position of these drugs as markers of COPD severity. High practice
rates of prescribing of LAMA and LABA+ICS may have indicated
those practices with high prevalence of COPD patients with severe
and very severe disease, those most at risk of admission. The rising
volume of prescribing of these drugs at the practice level appears
to have been an increasingly accurate indicator of admission risk
within practices.
Implications for future research, policy and practice
As this study examined practice-level associations between
prescribing and admissions, future work should assess the
relationship between medication use and hospital admissions
among individual COPD patients within practices. The importance
of these ﬁndings may warrant a phase IV clinical trial to assess
whether the marginal beneﬁts seen within phase III trials persist
within everyday clinical practice.
Conclusions
The proven effectiveness of LAMA and LABA+ICS in reducing
exacerbations has been followed by some scepticism about their
role in reducing admissions.4,6,10,13 That scepticism is supported
by the results of our study. Higher practice prescribing of these
drugs was associated with higher rates of COPD admission. Data
from the NHSBSA show that spending on these two groups of
drugs in 2011 totalled nearly £650 million per year in England. This
is a huge ﬁnancial burden to the UK taxpayer from the widespread
use of prescription drugs, the extent of effectiveness of which in
COPD is uncertain.
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